Cargando…

Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need

OBJECTIVE: The lack of standardised outcomes and outcome measures for cutaneous lupus erythematosus (CLE) represents a substantial barrier to clinical trial design, comparative analysis and approval of novel investigative treatments. We aimed to develop a working core outcome set (COS) for CLE rando...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Lisa N, Perez-Chada, Lourdes M, Borucki, Robert, Nambudiri, Vinod E, Werth, Victoria P, Merola, Joseph F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Cutaneous Lupus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718411/ https://www.ncbi.nlm.nih.gov/pubmed/34969875 http://dx.doi.org/10.1136/lupus-2021-000529

Ejemplares similares

Robust measurement of clinical improvement in patients with cutaneous lupus erythematosus
por: Nanes, Benjamin A, et al.
Publicado: (2020)

State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus
por: Zhao, Megan, et al.
Publicado: (2023)

Cutaneous lupus concerns from the patient perspective: a qualitative study
por: Yan, Daisy, et al.
Publicado: (2021)

Depression, stigma and social isolation: the psychosocial trifecta of primary chronic cutaneous lupus erythematosus, a cross-sectional and path analysis
por: Drenkard, Cristina, et al.
Publicado: (2022)

Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program
por: Izmirly, Peter, et al.
Publicado: (2019)

Panoramic view of clinical features of lupus erythematosus: a cross-sectional multicentre study from China
por: Jin, Hui, et al.
Publicado: (2023)

Plucked hair follicles from patients with chronic discoid lupus erythematosus show a disease-specific molecular signature
por: Shalbaf, Mohammad, et al.
Publicado: (2019)

Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
por: Tanaka, Yoshiya
Publicado: (2023)

Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE
por: Xie, Han, et al.
Publicado: (2023)

Systemic lupus erythematosus: state of the art on clinical practice guidelines
por: Tamirou, Farah, et al.
Publicado: (2019)

Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus
por: AlE'ed, Ashwaq, et al.
Publicado: (2018)

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
por: Morand, Eric, et al.
Publicado: (2023)

Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2020)

Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies
por: Holmqvist, Marie, et al.
Publicado: (2015)

Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry
por: Rector, Ian, et al.
Publicado: (2023)

Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosus
por: You, Hanxiao, et al.
Publicado: (2023)

Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis
por: Yazdany, Jinoos, et al.
Publicado: (2020)

White matter hyperintensities associate with cognitive slowing in patients with systemic lupus erythematosus and neuropsychiatric symptoms
por: Monahan, Rory Caitlin, et al.
Publicado: (2021)

Endothelial dysfunction is associated with activation of the type I interferon system and platelets in patients with systemic lupus erythematosus
por: Tydén, Helena, et al.
Publicado: (2017)

Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in an academic tertiary care centre
por: Schmidtmann, Irene, et al.
Publicado: (2023)

Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus
por: Strasser, Daniel S, et al.
Publicado: (2020)

Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus
por: Elefante, Elena, et al.
Publicado: (2020)

Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus
por: Mertz, Philippe, et al.
Publicado: (2022)

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial
por: Wang, Huijing, et al.
Publicado: (2022)

Performance of the proposed ACR–EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms
por: Gegenava, Maka, et al.
Publicado: (2019)

Circulating mitochondrial DNA copy numbers represent a sensitive marker for diagnosis and monitoring of disease activity in systemic lupus erythematosus
por: Giaglis, Stavros, et al.
Publicado: (2021)

Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study
por: Floris, Alberto, et al.
Publicado: (2022)

The impact of upper limb exercise on function, daily activities and quality of life in systemic lupus erythematosus: a pilot randomised controlled trial
por: Keramiotou, Kyriaki, et al.
Publicado: (2020)

Increased risk of congenital malformations in offspring born to women with systemic lupus erythematosus in South Korea: a nationwide population-based study
por: Jung, Young Mi, et al.
Publicado: (2023)

Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience
por: Tani, Chiara, et al.
Publicado: (2019)

Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
por: Zhang, Fengchun, et al.
Publicado: (2022)

Validation of a machine learning approach to estimate Systemic Lupus Erythematosus Disease Activity Index score categories and application in a real-world dataset
por: Alves, Pedro, et al.
Publicado: (2021)

Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations
por: Drosos, George C, et al.
Publicado: (2023)

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Candidate drug replacements for quinacrine in cutaneous lupus erythematosus
por: Yan, Daisy, et al.
Publicado: (2020)

Genetic dissection of HLA-DRB1*15:01 and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role for HLA-DRB1*15:01
por: Kawasaki, Aya, et al.
Publicado: (2023)

Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021
por: Calabrese, Cassandra, et al.
Publicado: (2023)

Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2019)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Biological impact of iberdomide in patients with active systemic lupus erythematosus
por: Lipsky, Peter E, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m734e98n6gc21jq8d2uva6b791